November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
4 citations
,
October 2021 in “Scientific Reports” NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.
5 citations
,
February 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” Rapamycin may help treat Leigh syndrome by targeting protein kinase C.
May 2018 in “The Journal of Immunology” A(1-7) treatment reduces symptoms of lupus in mice.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
July 2022 in “Journal of Investigative Dermatology” Inhibiting TYK2 can restore hair growth in alopecia areata.
April 2017 in “Journal of Investigative Dermatology” Targeted siRNA therapy may be a promising treatment for KID syndrome by reducing mutant gene expression and improving cell communication.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
55 citations
,
October 2015 in “Journal of Investigative Dermatology” Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
26 citations
,
December 2020 in “Nature metabolism” Rapamycin treatment helps with mitochondrial disease by reducing PKC levels.
August 2025 in “International Journal of Women’s Dermatology” Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
December 2017 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
July 2025 in “Frontiers in Medicine” Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
September 2023 in “Frontiers in bioengineering and biotechnology” JAGGED1 could help regenerate tissues for bone loss and heart damage if delivered correctly.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
3 citations
,
April 2024 in “International Journal of Women’s Dermatology” Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
9 citations
,
August 2020 in “International Journal of Molecular Sciences” New compounds may help treat heart disease by activating specific potassium channels.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
April 2025 in “Drug Design Development and Therapy” Jiawei Erzhiwan helps hair growth in androgenetic alopecia by affecting specific cell pathways.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
1 citations
,
October 2017 JAK inhibitors are effective for hair regrowth in severe alopecia areata.